Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 7/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 7/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 7/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 7/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3905057 | 0.92 | ESR2 (0.61) | ESR2CHRM4CHRM2DRD2HTR7 | |
| SCHEMBL30674388 | 0.89 | ESR2 (0.55) | ESR2BRD4KDM4EMPOPDK1 | |
| SCHEMBL3653863 | 0.89 | ESR2 (0.55) | ESR2BRD4KDM4EMPOPDK1 | |
| SCHEMBL6109833 | 0.89 | ESR2 (0.46) | ESR2CHRM4CHRM2BRD4DRD2 | |
| SCHEMBL15074680 | 0.86 | KDM4E (0.58) | ESR2CHRM4BRD4DRD2HTR7 | |
| SCHEMBL17795396 | 0.85 | BRD4 (0.45) | ESR2CHRM4CHRM2BRD4DRD2 | |
| SCHEMBL29631022 | 0.85 | ALDH1A1 (0.45) | ESR2CHRM4BRD4DRD2HTR7 | |
| SCHEMBL398708 | 0.85 | BRD4 (0.59) | ESR2CHRM4BRD4DRD2HTR7 | |
| SCHEMBL29507021 | 0.85 | BRD4 (0.45) | ESR2CHRM4BRD4DRD2HTR7 | |
| SCHEMBL29984623 | 0.85 | BRD4 (0.59) | ESR2CHRM4BRD4DRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086959-B1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | disclosed |
| EP-2086959-B1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-20110264029-A1 | IONTOPHORETIC DELIVERY SYSTEM | Kopman, Stanley E. (CA) | 2011-10-27 | — | — | US | disclosed |
| US-7858652-B2 | Substituted 4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858652-B2 | Substituted 4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858652-B2 | Substituted 4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7834044-B2 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMAN-LAROCHE INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834044-B2 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMAN-LAROCHE INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834044-B2 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMAN-LAROCHE INC. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-2086959-A1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008058867-A2 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008058867-A2 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | WO | disclosed |
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMANN-LA ROCHE, INC. | 2008-05-15 | — | — | US | disclosed |
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMANN-LA ROCHE, INC. | 2008-05-15 | — | — | US | disclosed |
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMANN-LA ROCHE, INC. | 2008-05-15 | — | — | US | disclosed |
| WO-2008052907-A1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008052907-A1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20060167046-A1 | Histamine h3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2006-07-27 | — | — | US | disclosed |
| EP-1585731-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATON AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004026837-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATON AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | TAAR1, TAAR5, MCHR1 | ESR2 2771/4885CHRM4 1013/4885CHRM2 546/4885 |
| US-20060167046-A1 | Histamine h3 receptor antagonists, preparation and therapeutic uses | HRH3, HRH4, HRH2 | ESR2 1773/4885CHRM4 326/4885CHRM2 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.